Here's what we'll cover
Here's what we'll cover
You're taking your weekly injection, eating better, and seeing results. But what if a single biological discovery could make that same medication work even harder for you?
That's the promise behind new research identifying an enzyme that appears to control how quickly GLP-1 — the hormone that drugs like semaglutide (Ozempic, Wegovy) are designed to mimic — gets broken down in the body.
The key takeaway: Scientists may have found a way to enhance GLP-1 therapy at the molecular level, which could eventually lead to stronger treatments with potentially fewer side effects or lower doses.
What Exactly Did Scientists Find?
Researchers identified a specific enzyme that degrades GLP-1 in the body faster than previously understood. When this enzyme is active, it shortens how long the GLP-1 hormone can do its job — signaling fullness, regulating insulin, and slowing digestion.
The discovery is significant because it gives scientists a concrete biological target. Rather than just delivering more of the hormone (which is essentially what current injections do), future drugs might work by blocking this enzyme — letting your body's own GLP-1 last longer and work more efficiently.
Think of it like this: instead of pouring more water into a leaking bucket, you'd be patching the hole.
Why This Matters If You're Already on a GLP-1 Medication
If you're currently on semaglutide or tirzepatide, this research doesn't change anything about your treatment today. But it does matter for the bigger picture.
Current GLP-1 medications are already engineered to resist rapid breakdown — that's partly why semaglutide only needs to be injected once a week. This new enzyme discovery suggests there may still be room to go further, potentially making future formulations even more durable and effective.
For patients who experience plateaus or don't respond as strongly to current doses, enzyme-targeted therapies could one day offer an alternative or complementary approach. More response from the same biological pathway, with a different mechanism.
The Science Behind GLP-1 Degradation
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in your gut after eating. In people without metabolic dysfunction, it plays a smooth, automatic role in appetite regulation and blood sugar control.
The problem: natural GLP-1 breaks down within minutes. That's why synthetic versions like semaglutide were developed — they're chemically modified to resist degradation and stay active for days.
An enzyme called DPP-4 has long been known to break down GLP-1, and drugs called DPP-4 inhibitors (like sitagliptin) already exist to slow that process. This new research points to an additional or alternative enzyme pathway — one that hasn't been fully targeted before. That's a meaningful gap in our current understanding, now closing.
Could This Lead to an "Ozempic Plus" Type Drug?
It's worth being measured here. Basic science discoveries like this one are exciting, but they sit at the beginning of a long development process. Moving from "we found an enzyme" to "here's an approved medication" typically takes a decade or more, multiple clinical trials, and regulatory review.
That said, this kind of mechanistic discovery is exactly how new drug classes get born. DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors — all of them trace back to foundational science like this.
What researchers may explore next: whether blocking this enzyme in combination with existing GLP-1 agonists produces additive effects, or whether an enzyme inhibitor alone could work for patients who can't tolerate current injectable therapies.
What This Means for the Future of Obesity and Diabetes Treatment
The GLP-1 space is already moving fast. Tirzepatide targets both GLP-1 and GIP receptors. Retatrutide adds a third hormone pathway. Oral semaglutide is now available for type 2 diabetes, with an obesity-dose version in development.
Enzyme-targeting therapy would represent yet another angle of attack — one that works with your body's own biology rather than introducing a synthetic hormone analog.
For the millions of people managing obesity, type 2 diabetes, or both, more options with different mechanisms means better ability to personalize treatment. Not everyone responds to GLP-1 drugs the same way. Having alternative or complementary pathways could eventually help patients who plateau, those with tolerability issues, or those who regain weight after stopping current medications.
The field is moving toward a future where metabolic disease is treated with layered, targeted precision — much like oncology has done over the past 20 years.
Bottom Line
Scientists have identified an enzyme that degrades GLP-1 in the body, potentially faster and through a different pathway than previously known. Blocking this enzyme could become a new strategy to enhance or extend the effectiveness of GLP-1 therapy.
This research is early-stage and won't change your current treatment. But it's a meaningful scientific step — one that could eventually lead to more effective, personalized options for people managing obesity and type 2 diabetes.
If you're curious about how your current GLP-1 medication works or whether newer options might be right for you, talk to your prescribing physician. The science is evolving, and staying informed puts you in the best position to make good decisions with your care team.
Considering GLP-1 therapy or want to understand your current treatment better? Explore our medication guides and science explainers to stay ahead of the research.
No waiting list. No insurance needed.
Frequently Asked Questions
What enzyme did scientists discover and why does it matter?
Researchers identified a specific enzyme that degrades GLP-1 in the body faster than previously understood through a pathway beyond the already-known DPP-4 enzyme. When this enzyme is active, it shortens how long GLP-1 can perform its functions of signaling fullness, regulating insulin, and slowing digestion. The discovery matters because it gives scientists a concrete new biological target: rather than just delivering more synthetic hormone, future drugs might block this enzyme and let the body's own GLP-1 last longer and work more efficiently.
Does this discovery change my current GLP-1 treatment?
No. This is early-stage foundational science that does not affect current medications or dosing. Semaglutide and tirzepatide are already engineered to resist rapid breakdown, which is why semaglutide only needs to be injected once weekly. This discovery suggests there may be additional room to improve durability and effectiveness in future formulations, but those applications are years away from clinical availability.
How is this different from DPP-4 inhibitors that already exist?
DPP-4 inhibitors like sitagliptin already target one known enzyme that breaks down GLP-1. This new research points to an additional or alternative enzyme pathway that has not been fully targeted before. That means even patients already benefiting from DPP-4 inhibition may have a second degradation pathway actively shortening their GLP-1 activity. Targeting this second pathway could produce additive effects or offer an alternative for patients who do not respond well to existing approaches.
Could blocking this enzyme eventually replace injectable GLP-1 medications?
It is unlikely to replace them entirely, but it could complement or enhance them. Researchers may explore whether blocking this enzyme in combination with existing GLP-1 agonists produces additive effects, or whether an enzyme inhibitor alone could work for patients who cannot tolerate current injectable therapies. The goal would be to get more response from the same biological pathway through a different mechanism, not necessarily to eliminate the need for GLP-1 agonists.
How long before a drug based on this discovery might be available to patients?
Moving from a foundational enzyme discovery to an approved medication typically takes a decade or more, including multiple phases of clinical trials and regulatory review. This places any enzyme-targeting therapy well into the 2030s at the earliest under optimistic scenarios. Patients currently on GLP-1 therapy should focus on optimizing their current treatment rather than waiting for future options that have no guaranteed timeline.
What does this mean for patients who have stopped responding to their current GLP-1 dose?
For patients who experience plateaus or do not respond as strongly as expected to current doses, enzyme-targeted therapies could one day offer an alternative or complementary approach. However, that is a future possibility rather than a current solution. If you are experiencing a plateau now, the most productive step is to discuss it with your prescribing physician, who can evaluate whether a dose adjustment, a switch to tirzepatide, or additional lifestyle interventions might improve your response within currently available options.